Postoperative Pain Following Eye Enucleation: A Prospective Observational Study.

Background and Objectives: Enucleation of an eye is the most invasive procedure in ophthalmologic surgery. It can be the result of various diseases (malignant/chronic/trauma/infection) and is nevertheless relatively rare, but leads to the loss of a strongly innervated neuronal organ. This study systematically evaluates postoperative pain levels following enucleation of the eye globe. Materials and Methods: This prospective single-center study enrolled twenty-four patients undergoing enucleation of the eye globe. Perioperatively all patients completed (preoperative day, day of surgery, 1st, 2nd, and 3rd day following surgery) standardized questionnaires concerning their pain experience and treatment-related side-effects (internal protocol, QUIPS, painDETECT®). Patients received usual pain therapy in an unstandardized individual manner. Results: Preoperatively, mean average pain intensity of all included patients was 3.29 ± 2.46 (range, 0-8), 3.29 ± 3.24 (range, 0-8) on the day of surgery, 4.67 ± 1.90 (range, 2-10) on day 1, 3.25 ± 1.39 (range, 1-6) on day 2, and 2.71 ± 1.30 (range, 1-6) on day 3 after surgery. Mean maximum pain intensity was 4.71 ± 3.28 (range, 0-10) preoperatively, 4.04 ± 3.78 (range, 0-10) on the day of surgery, 5.75 ± 2.01 (range, 2-10) on day 1, 4.25 ± 1.89 (range, 2-10) on day 2, and 3.88 ± 1.54 (range, 2-8) on day 3 after surgery. Nineteen patients (79.2%) stated that they would have preferred more pain therapy. Conclusions: Patients undergoing eye enucleation report pain sensations in need of intervention in this university hospital. Thus, effective standardized pain treatment concepts are now a high priority to be established in an interdisciplinary manner containing standardized regimens and continuous regional procedures. Awareness of this problem in the medical team should be sharpened through targeted training and information.

Electricity consumption of anesthesia workstations and potential emission savings by avoiding standby.

BACKGROUND: Anesthesiology has a relevant carbon footprint, mainly due to volatile anesthetics (scope 1 emissions). Additionally, energy used in the operating theater (scope 2 emissions) contributes to anesthesia-related greenhouse gas (GHG) emissions. OBJECTIVES: Optimizing the electricity use of medical devices might reduce both GHG emissions and costs might hold potential to reduce anaesthesia-related GHG-emissions and costs. We analyzed the electricity consumption of six different anesthesia workstations, calculated their GHG emissions and electricity costs and investigated the potential to reduce emissions and cost by using the devices in a more efficient way. METHODS: Power consumption (active power in watt , W) was measured with the devices off, in standby mode, or fully on with the measuring instrument SecuLife ST. Devices studied were: Dräger Primus, Löwenstein Medical LeonPlus, Getinge Flow C, Getinge Flow E, GE Carestation 750 and GE Aisys. Calculations of GHG emissions were made with different emission factors, ranging from very low (0.09 kg CO2-equivalent/kWh) to very high (0.660 kg CO2-equivalent/kWh). Calculations of electricity cost were made assuming a price of 0.25 € per kWh. RESULTS: Power consumption during operation varied from 58 W (GE CareStation 750) to 136 W (Dräger Primus). In standby, the devices consumed between 88% and 93% of the electricity needed during use. The annual electricity consumption to run 96 devices in a large clinical department ranges between 45 and 105 Megawatt-hours (MWh) when the devices are left in standby during off hours. If 80% of the devices are switched off during off hours, between 20 and 46 MWh can be saved per year in a single institution. At the average emission factor of our hospital, this electricity saving corresponds to a reduction of GHG emissions between 8.5 and 19.8 tons CO2-equivalent. At the assumed prices, a cost reduction between 5000 € and 11,600 € could be achieved by this intervention. CONCLUSION: The power consumption varies considerably between the different types of anesthesia workstations. All devices exhibit a high electricity consumption in standby mode. Avoiding standby mode during off hours can save energy and thus GHG emissions and cost. The reductions in GHG emissions and electricity cost that can be achieved with this intervention in a large anesthesiology department are modest. Compared with GHG emissions generated by volatile anesthetics, particularly desflurane, optimization of electricity consumption of anesthesia workstations holds a much smaller potential to reduce the carbon footprint of anesthesia; however, as switching off anesthesia workstations overnight is relatively effortless, this behavioral change should be encouraged from both an ecological and economical point of view.

Immediate postoperative topical lidocaine gel for the treatment of eye pain following corneal abrasion in descemet membrane endothelial keratoplasty (DMEK) under general anaesthesia: a pilot retrospective analysis.

BACKGROUND: Patients undergoing corneal abrasion as part of Descemet membrane endothelial keratoplasty (DMEK) under general anesthesia suffer from early burning pain postoperatively. This pain appears to be poorly treatable with systemic analgesics. This study aims to evaluate postoperative pain management using topical lidocaine gel after DMEK with iatrogenic corneal abrasion. METHODS: Retrospective analysis of 28 consecutive patients undergoing DMEK with corneal abrasion from October 19, 2021, to November 12, 2021, at a German university hospital. Patients during week 1 and 2 received peri-operative standard pain treatment (cohort S) and additional local lidocaine gel during week 3 and 4 immediately postoperatively (cohort L). RESULTS: 13 patients were included in cohort S and 15 patients in cohort L. At awakening all patients (100%) in cohort S reported burning pain, and six of 15 patients (40%) in cohort L reported burning pain. Burning pain scores were significantly lower in cohort L (p < 0.001 at awakening, p < 0.001 at 10 min, p < 0.001 at 20 min, p < 0.001 at 30 min, p = 0.007 at 40 min after awakening, and p < 0.001 at leaving recovery room). No significant differences between cohort S and cohort L were detected concerning surgical outcome during 1-month-follow-up (p = 0.901 for best corrected visual acuity). CONCLUSION: Patients undergoing DMEK with corneal abrasion suffer significant pain in the recovery room. A single dose of topic lidocaine gel reduces the early postoperative burning pain sufficiently and does not affect the surgical outcome.

[Pain therapy in children following ophthalmic surgery]. / Schmerztherapie bei Kindern nach ophthalmochirurgischen Eingriffen.

Pain following eye surgery is often described as being relatively moderate; however, there are also procedures that lead to a pronounced pain experience. Particularly in pediatric patients, pain therapy is often insufficient due to a lack of knowledge and fear of complications. These individual and organizational deficits lead to unnecessary discomfort for children and parents. Each institution providing surgical treatment must have pain management concepts in its portfolio for the appropriate age groups. This includes a child-oriented setting, age-appropriate information, systematic pain assessment, and pain protocols. Pain management should be planned prior to surgery and individually adapted as it progresses. Children have a right to a perioperative course with low stress and pain.

Habilidades auditivas em adultos jovens com e sem percepção de zumbido: um estudo de comparações / Auditory skills in young adults with and without tinnitus perception: a comparative study

RESUMO Objetivo analisar as respostas do processamento das informações auditivas em sujeitos adultos jovens com transtorno do zumbido. Métodos estudo de caráter descritivo e quantitativo. Participaram do estudo 36 sujeitos, com idades entre 19 e 35 anos, divididos em dois grupos: Grupo 1 (20 sujeitos com zumbido crônico) e Grupo 2 (16 sujeitos sem zumbido). Todos os indivíduos foram submetidos à anamnese, inspeção visual do meato acústico externo, audiometria tonal liminar, logoaudiometria, medidas de imitância acústica e, como instrumentos de avaliação, os testes comportamentais do processamento auditivo central - Teste Dicótico de Dígitos, Teste Padrão de Frequência, Teste de Fala no Ruído, Masking Level Difference e Gap in Noise. Resultados existiram diferenças estatisticamente significativas entre os grupos para as respostas do Teste Dicótico de Dígitos na orelha esquerda e para o Gap in Noise em ambas as orelhas. Conclusão adultos jovens com zumbido crônico apresentam prejuízo nas habilidades de integração binaural e resolução temporal.

ABSTRACT Purpose Objective: To analyze auditory information processing responses in young adult subjects with tinnitus disorder. Methods A descriptive and quantitative study was conducted, involving 36 subjects aged between 19 and 35 years. The subjects were divided into two groups: Group 1 (20 subjects with chronic tinnitus) and Group 2 (16 subjects without tinnitus). All participants underwent medical history assessment, Visual Inspection of the External Auditory Canal, Pure-Tone Audiometry, Speech Audiometry, Acoustic Immittance Measures, and used Behavioral Central Auditory Processing Tests as an evaluation tool - Dichotic Digits Test (TDD), Frequency Pattern Test, Speech in Noise, Masking Level Difference, and Gap in Noise (GIN). Results Statistically significant differences were found between the groups for TDD responses in the left ear and for GIN in both ears. Conclusion Young adults with chronic tinnitus exhibit impairments in binaural integration and temporal resolution skills.

Severe Hypotension With Concomitant Sodium-Glucose Co-Transporter-2 Inhibitor and Angiotensin Receptor-Neprilysin Inhibitor Therapy in a Patient With Heart Failure Reduced Ejection Fraction: A Case Report.

Background: Large cardiovascular outcomes trials in individuals with heart failure, with and without diabetes, have demonstrated a significant risk reduction in the composite outcome of cardiovascular death or hospitalizations for heart failure with SGLT2 inhibitor therapy. These positive outcomes have led to the recommendation that SGLT2 inhibitors serve as backbone therapy in patients with heart failure reduced ejection fraction (HFrEF). To date, there has not been enough participants in clinical trials on concomitant SGLT2 inhibitor and angiotensin receptor-neprilysin inhibitor therapy to evaluate the benefits and risks of combination therapy with these two agents outside of smaller subgroup analyses. Case Summary: This case describes a Black female with diabetes meeting her glycemic targets and concomitant stable NYHA FC II HFrEF on guideline-directed medical therapy (GDMT) with sacubitril/valsartan, spironolactone and metoprolol succinate who developed severe hypotension and dehydration requiring hospitalization after initiation of SGLT2 inhibitor therapy. Practice Implications: This case report raises the question of whether those with type 2 diabetes, and/or those on background angiotensin receptor-neprilysin inhibitor therapy, who are euvolemic or sensitive to diuretic therapy should be started on lower dose dapagliflozin and titrated to 10 mg daily based on response. It also raises awareness to the potential increased diuretic effect produced with concomitant use of sacubitril/valsartan and dapagliflozin. Caution and education to mitigate the risk for volume depletion should be provided to those patients who are euvolemic and initiated on a SGLT2 inhibitor, regardless of their background diuretic and GDMT. Conclusion: Future research should focus on the benefits and safety considerations and provide education on how to best initiate and adjust SGLT2 inhibitors in the setting of sacubitril/valsartan use in diverse heart failure patient populations.

A misdiagnosis of type 2 diabetes mellitus: Using continuous glucose monitoring to improve patient-centered care.

BACKGROUND: The American Diabetes Association recommends glycosylated hemoglobin (A1C) to assess the management of diabetes mellitus (DM) and provides specific A1C goals to reduce the risk of DM-related complications. Although A1C is a convenient test to diagnose and monitor DM management over a 3-month time frame, certain conditions may affect the accuracy of the A1C. CASE SUMMARY: This case describes a woman diagnosed as having type 2 DM based on multiple A1C levels > 10%. The patient was treated by her primary care provider based on her A1C and was experiencing hypoglycemic and adverse events, despite a consistently elevated A1C. Discrepancies were noted between A1C results, random glucose monitoring at office visits, home blood glucose monitoring, and clinical presentation. Professional-use continuous glucose monitoring (CGM) and fructosamine levels were used to further assess the patient's glycemic management. The patient was found to have a hemoglobin (Hb) Wayne variant by Hb electrophoresis and demonstrated a misdiagnosis of type 2 DM. PRACTICE IMPLICATIONS: This report describes the importance of patient and clinician communication and highlights the limitations of using A1C levels that should be taken into consideration when the clinical picture does not align with the laboratory assessment. It also demonstrates the value of CGM technology for patients and offers a unique approach to using the ambulatory glucose profile report to promote engaging discussions with patients.

Cultivating best practices in care transitions through comprehensive medication management.

An estimated 20% of patients experience a postdischarge adverse event in the 30 days after hospital discharge, with approximately two-thirds of these events considered preventable or ameliorable. Numerous transitional care interventions have been developed and implemented by clinical pharmacists to reduce postdischarge adverse drug events and readmissions; however, most efforts are focused on the admission and discharge process. Low-quality evidence and mixed results from evaluations of postdischarge interventions have left health care organizations unsure which interventions provide the greatest value and how to optimize their implementation. Comprehensive medication management (CMM) is an approach, usually delivered by a pharmacist in collaboration with the health care team, which aims to standardize the wide variability in medication-specific pharmacist-led services to optimize medication use and improve clinical outcomes. This article aims to discuss how CMM can be used to cultivate best practices in care transitions.

Frequency-Following Response and Auditory Middle Latency Response: an analysis of central auditory processing in young adults / Frequency-Following Response e Potencial Evocado Auditivo de Média Latência: uma análise frente ao processamento auditivo central de jovens adultos

ABSTRACT Purpose: to compare the latency and amplitude of the Frequency-Following Response and the Auditory Middle Latency Response in typical individuals and those with altered auditory abilities, as well as to investigate the sensitivity and specificity of both assessments in relation to central auditory processing. Methods: 32 individuals of both sexes were distributed into Group 1 (without altered auditory abilities) and Group 2 (with altered auditory abilities). The groups were divided according to behavioral tests of central auditory processing. Individuals in both groups underwent auditory evoked potentials. Student's t-test was used for analysis, considering a 5% significance. Results: in Group 2, V and A had higher latency and lower amplitude and slope. Group 2 also had lower Na and Pa amplitudes in waves A1C3 and A2C3. The Frequency-Following Response showed 93% sensitivity and specificity, while the Auditory Middle Latency Response showed 87% sensitivity and 93% specificity. Conclusion: the individuals presented with altered hearing abilities showed higher latency and lower response amplitude in the Frequency Following Response and Auditory Middle Latency Response compared to typical individuals. The Frequency- Following Response showed a better balance of sensitivity and specificity.

RESUMO Objetivo: comparar a latência e a amplitude do Frequency-Following Response e do Potencial Evocado Auditivo de Média Latência em indivíduos típicos e com alterações das habilidades auditivas, assim como investigar a sensibilidade e especificidade de ambas as avaliações frente ao processamento auditivo central. Métodos: 32 indivíduos de ambos os sexos foram distribuídos em Grupo 1 (sem alterações de habilidades auditivas) e Grupo 2 (com alteração em habilidades auditivas). Os grupos foram divididos de acordo com testes comportamentais do processamento auditivo central. Os indivíduos de ambos os grupos foram submetidos aos potenciais evocados auditivos. O teste T de Student foi utilizado para a análise, considerando 5% de significância. Resultados: no Grupo 2, V e A apresentaram maior latência e menor amplitude e slope. O Grupo 2 também apresentou menores amplitudes de Na e Pa nas ondas A1C3 e A2C3. O Frequency-Following Response apresentou 93% de sensibilidade e especificidade, enquanto o Potencial Evocado Auditivo de Média Latência apresentou 87% de sensibilidade e 93% de especificidade. Conclusão: os indivíduos com alteração das habilidades auditivas apresentaram maior latência e menor amplitude de resposta no Frequency Following Response e Potencial Evocado Auditivo de Média Latência em relação aos indivíduos típicos. O Frequency-Following Response apresentou melhor equilíbrio de sensibilidade e especificidade.

Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors.

BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are associated with an increased risk of genitourinary infections in patients with type 2 diabetes mellitus (T2DM). It is unknown which factors may predispose patients to an increased risk of developing a genitourinary infection. OBJECTIVE: To evaluate whether hemoglobin A1c levels and other patient-specific factors at initiation of SGLT2 inhibitor therapy were a predictor for increased risk for genitourinary infections. METHODS: A retrospective, multicenter cohort analysis was conducted using data from ambulatory care clinics within a large medical group. Patients 18 years of age or older with a diagnosis of T2DM who were prescribed a SGLT2 inhibitor between January 1, 2013 and October 31, 2018 and completed therapy for at least seven days were included in the analysis. Firth logistic regression was used to detect differences in baseline characteristics and paired t-tests were used to compare baseline to post-initiation values for prespecified variables for those patients with a confirmed genitourinary infection. RESULTS: Of the 739 patients prescribed a SGLT2 inhibitor, 584 were included. Thirty (5.14%) patients experienced a genitourinary infection on SGLT2 inhibitor therapy. Baseline hemoglobin A1c did not confer a significant difference in risk for genitourinary infection (p=0.4239). Estimated glomerular filtration rate (eGFR) was the only variable that significantly differed between those who did and did not develop an infection (p=0.0228). A post hoc analysis reviewing 30 patients initially excluded for a history of genitourinary infection showed 13 (43%) of those patients experienced a genitourinary infection after initiating SGLT2 inhibitor therapy with no difference in risk stratified by baseline hemoglobin A1c level (p=0.9648). CONCLUSIONS: The incidence of genitourinary infection with SGLT2 inhibitor use was lower than suggested in clinical trials, with lower eGFR and history of genitourinary infection the only identified predictors for increased risk in this population. Genitourinary infection risk should not deter clinicians from recommending or prescribing SGLT2 inhibitor therapy.

Severe Hyponatraemia Associated with the Use of Arginine-Vasopressin in Two Neonates with Complex Congenital Heart Disease.

We report two cases of neonates with complex congenital heart disease and volume, catecholamine, and corticosteroid refractory shock treated with arginine-vasopressin. Arginine-vasopressin was able to reverse critical hypotension, but both patients developed severe hyponatremia, which recovered after discontinuation of arginine-vasopressin. Close control and prompt substitution of serum sodium is required in neonates with advanced heart failure on high-dose vasopressin therapy.

SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.

STUDY OBJECTIVE: Currently only minimal information is available regarding risk factors for the development of sodium glucose cotransporter-2 inhibitor (SGLT2i)-related diabetic ketoacidosis (DKA). We aim to identify individual patient characteristics associated with cases of SGLT2i-related DKA to better describe potential risk factors. DESIGN: Systematic review of primary literature. PATIENTS: Thirty-four case reports of patients with type 1 and type 2 diabetes mellitus who developed DKA while receiving an SGLT2i. METHODS AND MAIN RESULTS: This systematic review investigated the relationship between SGLT2i and DKA in patients with diabetes. The existing literature was reviewed with a primary outcome to identify patient-specific factors contributing to the incidence of ketoacidosis in patients with diabetes who were treated with a SGLT2i. Numerous databases were searched to identify appropriate primary literature. Search terms included canagliflozin, dapagliflozin, empagliflozin, SGLT2, sodium glucose cotransporter-2 inhibitor, diabetic ketoacidosis, ketoacidosis, metabolic acidosis, and acidosis. Primary literature was analyzed via descriptive statistics. Thirty-four individual case reports were identified via the primary literature search. Two-thirds (25 cases) involved patients with a diagnosis of type 2 diabetes mellitus (T2DM). The average blood glucose on presentation for SGLT2i-induced DKA was 265.6 ± 140.7 mg/dl (14.7 ± 7.8 mmol/L), with common symptoms including nausea, vomiting, and abdominal pain. Common precipitating factors included patients who were diagnosed with T2DM and were subsequently found to have latent autoimmune diabetes of adulthood, patients who had recently undergone major surgery, or patients who had decreased or discontinued insulin. No cases were fatal. CONCLUSION: In this review, episodes of DKA with SGLT2i use were characterized by lower blood glucose levels and were often caused by a precipitating factor. Understanding precipitating factors for SGLT2i-related DKA may help providers better identify patients at risk for development of DKA.